Most Read Articles
Pearl Toh, 29 Apr 2019
Most of the vaccines routinely recommended in the US are safe with no evidence supporting a causal relationship between the vaccines and adverse events following immunization (AEFIs). Also, most of the AEFIs studied occurred rarely, according to a systematic review presented at the Pediatric Academic Societies (PAS) 2019 Meeting in Baltimore, Maryland, US.
21 Sep 2018
It is safe to revaccinate patients with a history of mild or moderate adverse events following immunization (AEFI), but more research is required in those with serious AEFIs who are less likely to be reimmunized, suggests a recent study.

Product Highlight - Zimilast 1000

20 Nov 2020
The Effective Choice
Against ESBL producing MDR pathogens


- Lower respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Gynecologic infections
- Bacterial septicemia
- Bone and joint infections
- Skin and skin structure infections
- Endocarditis
- Polymicrobial infections

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Pearl Toh, 29 Apr 2019
Most of the vaccines routinely recommended in the US are safe with no evidence supporting a causal relationship between the vaccines and adverse events following immunization (AEFIs). Also, most of the AEFIs studied occurred rarely, according to a systematic review presented at the Pediatric Academic Societies (PAS) 2019 Meeting in Baltimore, Maryland, US.
21 Sep 2018
It is safe to revaccinate patients with a history of mild or moderate adverse events following immunization (AEFI), but more research is required in those with serious AEFIs who are less likely to be reimmunized, suggests a recent study.